Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ABUS – Arbutus Biopharma Corporation

ABUS — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

10.74

Margin Of Safety %

Put/Call OI Ratio

0.7

EPS Next Q Diff

EPS Last/This Y

-0.06

EPS This/Next Y

Price

4.46

Target Price

5.25

Analyst Recom

1

Performance Q

-5.31

Upside

-152.5%

Beta

0.74

Ticker: ABUS




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09ABUS4.710.720.0239144
2026-03-10ABUS4.720.710.0939271
2026-03-11ABUS4.720.710.0239308
2026-03-12ABUS4.320.710.1539322
2026-03-13ABUS4.320.710.5139322
2026-03-17ABUS4.360.701.5739475
2026-03-18ABUS4.260.670.0038677
2026-03-19ABUS4.360.671.0038662
2026-03-20ABUS4.260.690.5042484
2026-03-23ABUS4.410.860.0017264
2026-03-24ABUS4.320.790.0418158
2026-03-25ABUS4.530.770.0118350
2026-03-26ABUS4.460.740.0118768
2026-03-27ABUS4.30.750.0018741
2026-03-30ABUS4.30.720.0019178
2026-03-31ABUS4.490.732.3819011
2026-04-01ABUS4.510.710.0018867
2026-04-02ABUS4.490.700.0018989
2026-04-06ABUS4.470.700.8919041
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09ABUS4.7244.9- -0.26
2026-03-10ABUS4.7144.9- -0.26
2026-03-11ABUS4.7244.9- -0.26
2026-03-12ABUS4.3244.9- -0.26
2026-03-13ABUS4.2644.9- -0.26
2026-03-17ABUS4.3644.9- -0.26
2026-03-18ABUS4.2644.9- -0.26
2026-03-19ABUS4.3644.9- -0.26
2026-03-20ABUS4.2444.9- -0.26
2026-03-23ABUS4.4144.9- -0.26
2026-03-24ABUS4.3244.9- -0.26
2026-03-25ABUS4.5344.9- -0.26
2026-03-26ABUS4.4644.9- -0.26
2026-03-27ABUS4.3044.9- -0.23
2026-03-30ABUS4.3069.7- -0.23
2026-03-31ABUS4.4969.7- -0.23
2026-04-01ABUS4.5169.7- -0.23
2026-04-02ABUS4.4969.7- -0.23
2026-04-06ABUS4.4669.7- -0.23
2026-04-07ABUS4.4669.7- -0.23
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09ABUS0.001.209.98
2026-03-10ABUS0.001.209.98
2026-03-11ABUS0.001.209.82
2026-03-12ABUS0.001.209.82
2026-03-13ABUS0.001.209.82
2026-03-17ABUS0.001.219.82
2026-03-18ABUS0.001.219.82
2026-03-19ABUS0.001.219.82
2026-03-20ABUS0.001.219.82
2026-03-23ABUS0.001.209.82
2026-03-24ABUS0.001.209.82
2026-03-25ABUS0.001.2010.92
2026-03-26ABUS0.001.2010.74
2026-03-27ABUS0.001.2010.74
2026-03-30ABUS0.001.1810.74
2026-03-31ABUS0.001.1810.74
2026-04-01ABUS0.001.1810.74
2026-04-02ABUS0.001.1810.74
2026-04-06ABUS0.001.1810.74
2026-04-07ABUS0.001.1810.74
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

Institutional Transactions

1.18

Beta

0.74

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

30

Growth Score

40

Sentiment Score

87

Actual DrawDown %

31.4

Max Drawdown 5-Year %

-63.4

Target Price

5.25

P/E

Forward P/E

PEG

P/S

61.92

P/B

11.21

P/Free Cash Flow

EPS

-0.18

Average EPS Est. Cur. Y​

-0.23

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-237.88

Relative Volume

0.38

Return on Equity vs Sector %

-71.2

Return on Equity vs Industry %

-54.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

ABUS Healthcare
$4.46
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
0/20
Pullback
15/25
Volume
8/15
Valuation
7/20
TP/AR
2/10
Options
0/10
RSI
51.5
Range 1M
41.1%
Sup Dist
1.1%
🚀
Momentum Growth
Ride accelerating trends
N/A
22 /100
WEAK
Momentum
3/25
Growth
14/30
Estimates
1/20
Inst/Vol
4/15
Options
0/10
EPS Yr
32.4%
EPS NY
0%
52W%
72.1%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟡 HOLD +17.7% upside
Quality
6/30
Valuation
4/30
Growth
9/25
Stability
8/10
LT Trend
0/5
Upside
+17.7%
Quality
30
Arbutus Biopharma Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 19
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
ABUS

Latest News

Caricamento notizie per ABUS
stock quote shares ABUS – Arbutus Biopharma Corporation Stock Price stock today
news today ABUS – Arbutus Biopharma Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch ABUS – Arbutus Biopharma Corporation yahoo finance google finance
stock history ABUS – Arbutus Biopharma Corporation invest stock market
stock prices ABUS premarket after hours
ticker ABUS fair value insiders trading